Clovis Lusivika‐Nzinga

893 total citations
8 papers, 68 citations indexed

About

Clovis Lusivika‐Nzinga is a scholar working on Epidemiology, Hepatology and Infectious Diseases. According to data from OpenAlex, Clovis Lusivika‐Nzinga has authored 8 papers receiving a total of 68 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Epidemiology, 6 papers in Hepatology and 2 papers in Infectious Diseases. Recurrent topics in Clovis Lusivika‐Nzinga's work include Hepatitis C virus research (6 papers), Liver Disease Diagnosis and Treatment (6 papers) and Liver Disease and Transplantation (3 papers). Clovis Lusivika‐Nzinga is often cited by papers focused on Hepatitis C virus research (6 papers), Liver Disease Diagnosis and Treatment (6 papers) and Liver Disease and Transplantation (3 papers). Clovis Lusivika‐Nzinga collaborates with scholars based in France and Egypt. Clovis Lusivika‐Nzinga's co-authors include Fabrice Carrat, Stanislas Pol, Céline Dorival, Hana Selinger‐Leneman, Sophie Grabar, Dominique Costagliola, Hélène Fontaine, Mélanie Simony, Carole Cagnot and Alpha Diallo and has published in prestigious journals such as The Journal of Infectious Diseases, BMC Medical Research Methodology and Pharmacoepidemiology and Drug Safety.

In The Last Decade

Clovis Lusivika‐Nzinga

8 papers receiving 65 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Clovis Lusivika‐Nzinga France 5 44 42 9 7 5 8 68
Pantong Davwar Nigeria 4 47 1.1× 47 1.1× 5 0.6× 11 1.6× 10 77
Jeff Linnen Canada 2 25 0.6× 24 0.6× 15 1.7× 3 0.4× 2 0.4× 2 43
Yasuyuki Aisaka Japan 5 80 1.8× 91 2.2× 13 1.4× 3 0.4× 5 1.0× 14 120
Pascal Migaud Germany 3 63 1.4× 56 1.3× 7 0.8× 6 0.9× 16 3.2× 8 82
Marieta Simonova Bulgaria 6 65 1.5× 61 1.5× 4 0.4× 5 0.7× 4 0.8× 8 72
Lei Hua United States 4 22 0.5× 17 0.4× 5 0.6× 4 0.6× 8 1.6× 9 52
Mahmoud Abdel-Aziz Egypt 5 20 0.5× 21 0.5× 12 1.3× 10 1.4× 2 0.4× 23 87
Sweta Chekuri United States 5 58 1.3× 76 1.8× 19 2.1× 7 1.0× 2 0.4× 7 104
Lamin Bojang Gambia 3 38 0.9× 42 1.0× 4 0.4× 6 0.9× 4 50
A.‐S. Duberg Sweden 7 102 2.3× 116 2.8× 9 1.0× 6 0.9× 4 0.8× 8 129

Countries citing papers authored by Clovis Lusivika‐Nzinga

Since Specialization
Citations

This map shows the geographic impact of Clovis Lusivika‐Nzinga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Clovis Lusivika‐Nzinga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Clovis Lusivika‐Nzinga more than expected).

Fields of papers citing papers by Clovis Lusivika‐Nzinga

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Clovis Lusivika‐Nzinga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Clovis Lusivika‐Nzinga. The network helps show where Clovis Lusivika‐Nzinga may publish in the future.

Co-authorship network of co-authors of Clovis Lusivika‐Nzinga

This figure shows the co-authorship network connecting the top 25 collaborators of Clovis Lusivika‐Nzinga. A scholar is included among the top collaborators of Clovis Lusivika‐Nzinga based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Clovis Lusivika‐Nzinga. Clovis Lusivika‐Nzinga is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Leducq, Valentin, Karen Zafilaza, Sophie Sayon, et al.. (2023). Spike Protein Genetic Evolution in Patients at High Risk of Severe Coronavirus Disease 2019 Treated by Monoclonal Antibodies. The Journal of Infectious Diseases. 229(5). 1341–1351. 4 indexed citations
2.
Roux, Marine, Jérémie Riou, Clémence M. Canivet, et al.. (2023). Dynamic personalized prediction of the individual liver‐related risk after sustained viral response in HCV patients. Journal of Viral Hepatitis. 30(6). 567–577. 5 indexed citations
3.
Dorival, Céline, Carole Cagnot, Hélène Fontaine, et al.. (2022). Prediction of hepatocellular carcinoma in Hepatitis C patients with advanced fibrosis after sustained virologic response. Clinics and Research in Hepatology and Gastroenterology. 46(6). 101923–101923. 14 indexed citations
4.
Fontaine, Hélène, Nathanaël Lapidus, Clovis Lusivika‐Nzinga, et al.. (2022). Performance of algorithms for identifying patients with chronic hepatitis B or C infection in the french health insurance claims databases using the ANRS CO22 HEPATHER cohort. Journal of Viral Hepatitis. 30(3). 232–241. 4 indexed citations
5.
Fontaine, Hélène, Nathanaël Lapidus, Céline Dorival, et al.. (2022). Impact of direct‐acting antiviral treatment for hepatitis C on cardiovascular diseases and extrahepatic cancers. Pharmacoepidemiology and Drug Safety. 32(4). 486–495. 11 indexed citations
6.
Lédinghen, Victor de, Clovis Lusivika‐Nzinga, Jean–Pierre Bronowicki, et al.. (2020). Sofosbuvir‐Daclatasvir is suboptimal in patients with genotype 2 chronic hepatitis C infection: real‐life experience from the HEPATHER ANRS CO22 cohort. Journal of Viral Hepatitis. 27(10). 964–973. 4 indexed citations
7.
Lusivika‐Nzinga, Clovis, Hélène Fontaine, Céline Dorival, et al.. (2019). The dynamic effect of direct‐acting antiviral treatments on the risk of hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis C. Journal of Viral Hepatitis. 26(12). 1489–1492. 13 indexed citations
8.
Lusivika‐Nzinga, Clovis, Hana Selinger‐Leneman, Sophie Grabar, Dominique Costagliola, & Fabrice Carrat. (2017). Performance of the marginal structural cox model for estimating individual and joined effects of treatments given in combination. BMC Medical Research Methodology. 17(1). 160–160. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pantong Davwar Breakdown of academic impact, for papers by Jeff Linnen Breakdown of academic impact, for papers by Yasuyuki Aisaka Breakdown of academic impact, for papers by Pascal Migaud Breakdown of academic impact, for papers by Marieta Simonova Breakdown of academic impact, for papers by Lei Hua Breakdown of academic impact, for papers by Mahmoud Abdel-Aziz Breakdown of academic impact, for papers by Sweta Chekuri Breakdown of academic impact, for papers by Lamin Bojang Breakdown of academic impact, for papers by A.‐S. Duberg
Rankless by CCL
2026